---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009380"
form_type: "8-K"
ticker: "LFMD"
cik: "0000948320"
company_name: "LifeMD, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:29:11.856989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026

## Summary
- FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).
- Q4 2025 revenue $46.9M (+4% YoY); adjusted EBITDA $4.8M (+348% YoY).
- Launched oral Wegovy post-year-end; >80% of new weight management patients using branded therapy; Q1 sign-ups at record levels.
- Ended 2025 with $36.8M cash, no debt; guides to annualized revenue >$250M and adj EBITDA >$25M by Q4 2026.
- Benefits infrastructure on track to cover ~220M Americans in Q2 2026; women's health seeing strong early growth.

## SEC filing metadata
- accession: 0001493152-26-009380
- form_type: 8-K
- ticker: LFMD
- cik: 0000948320
- company_name: LifeMD, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/948320/000149315226009380/0001493152-26-009380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/948320/000149315226009380/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009380
- JSON: https://secwatch.observer/filing/0001493152-26-009380.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.